Comparison of Two Dosing Regimens of Intravenous Ketorolac for Post-Cesarean Pain Control
NCT ID: NCT07244757
Last Updated: 2026-01-13
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
RECRUITING
NA
126 participants
INTERVENTIONAL
2025-12-01
2026-03-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
IV Ketorolac on Platelet Function Post-Cesarean Delivery
NCT03805607
Increased Ketorolac Administration After Cesarean Section and Its Effect on Opioid Use: a Randomized Control Trial
NCT03678675
Dosing of Ketorolac Impacts Post-cesarean paiN manaGemenet (KING)
NCT05248984
To Compare the Efficacy and Patients' Satisfaction for the Treatment of Post Cesarean Pain of Two Protocols: Oral Medications in Fixed Time Interval Administration Versus Spinal Morphine
NCT02440399
Post-cesarean Analgesia: Comparing Effectiveness of Staggered v. Simultaneous Therapies
NCT07102641
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
After closing the fascia, the subcutaneous layer will be infiltrated with 30 mL of 0.25% bupivacaine.
Postoperatively, if the Numeric rating scale is \> 3, intravenous nalbuphine 0.1 mg/kg titrated to response, with maximum single dose of 20 mg and maximum daily dose of 160 mg.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
PREVENTION
QUADRUPLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
ketorolac 30
patients will receive intravenous ketorolac at 30 mg/8 h postoperatively
Ketorolac 30 mg
administered intravenously as 30 mg diluted in 10 mL of normal saline and injected over more than 15 seconds
ketorolac 15 mg
patients will receive intravenous ketorolac at 15 mg/8 h postoperatively
Ketorolac 15mg
administered intravenously as either 15 mg diluted in 10 mL of normal saline and injected over more than 15 seconds.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Ketorolac 30 mg
administered intravenously as 30 mg diluted in 10 mL of normal saline and injected over more than 15 seconds
Ketorolac 15mg
administered intravenously as either 15 mg diluted in 10 mL of normal saline and injected over more than 15 seconds.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* aged 18-35 years,
* scheduled for elective cesarean delivery under spinal anesthesia
Exclusion Criteria
* multiple gestation. Patients with a history of allergy to any of the study drugs,
* renal impairment,
* gastrointestinal bleeding or ulceration
* inflammatory bowel disease,
* chronic pain or regular opioid use.
* Inability to comprehend the numeric pain scale (NRS) or the ObsQoR-11 score
* requirement for conversion to general anesthesia after spinal anesthesia
18 Years
35 Years
FEMALE
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Cairo University
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Ahmed Hasanin
professor
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
ahmed hasanin
Role: PRINCIPAL_INVESTIGATOR
Cairo University Kasr Alainy Faculty of Medicine
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Kasr Alainy Hospital
Cairo, , Egypt
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
MS-390-2025
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.